Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| F Medical imaging data management and analysis platform | $27.5M | Undisclosed | Healthtech | United States | Investors | |
| ET Enodia TherapeuticsCompany profile Develops small-molecule therapies for targeted protein degradation at the point of synthesis |
Ranked by rounds participated in · From Jan 1, 2026
Metriport, Arintra, Multiplier
Transfyr, General Intuition, Castelion
Rillet, Castelion, Hadrian
SiFly Aviation, Apollo Atomics, Hopscotch Primary Care
Higgsfield, Lovable, Cambridge Aerospace
Explore published rounds while the next edition is being prepared.
Develops small-molecule therapies for targeted protein degradation at the point of synthesis
| €20.7M |
| Seed |
| Biotech |
| France |
| Investors |
| E EpiBiologicsCompany profile Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo... Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo... | $107M | Series B | Biotech | United States | Investors |
| B BrightHeartCompany profile Develops AI-powered prenatal ultrasound platform for expert-level fetal heart screening and conge... Develops AI-powered prenatal ultrasound platform for expert-level fetal heart screening and conge... | €11M | Series A | AI | France | Investors |
| PD Perceptive DiscoveryCompany profile Provides preclinical and translational solutions for oncology and radiopharmaceutical programs Provides preclinical and translational solutions for oncology and radiopharmaceutical programs | $15M | StrategicUndisclosed | Biotech | United Kingdom | Investors |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners |
| A Develops specialized AI systems for regulated industries | $70M | Series B | AI | United States | Investors |
| U Provides a global clearing system for tokenised deposits and stablecoins | Undisclosed | StrategicUndisclosed | Fintech | United Kingdom | Investors |
| NT Nocion TherapeuticsCompany profile Develops novel small molecule therapies for treatment of serious conditions involving cough, itch... Develops novel small molecule therapies for treatment of serious conditions involving cough, itch... | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed |
| S STRM.BIOCompany profile Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy | $8M | Seed2Seed | Biotech | United States | Investors |